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Abstract  
Introduction: We investigated the prevalence, predictors of and effect of Antiretroviral Therapy (ART) regimen on cardiometabolic risk among 
HIV-positive Ugandan adults at enrolment into a prospective cohort to study the Complications of Long-Term ART (CoLTART). Methods: We 
collected data on cardiometabolic risk factors including dyslipidemia, hypertension, hyperglycemia, obesity and calculated the mean atherogenic 
index for Plasma (AIP) and 10 year Framingham risk score (FHS). Exposures were: ART regimen, duration on ART, demographic, socio-economic, 
behavioral, and life-style factors including smoking, physical activity and diet (including fruit and vegetables consumption). Results: We enrolled 
1024 participants, 65% female, mean age was 44.8 years (SD 8.0) and median duration on ART was 9.4 years (IQR 6.1-9.8). The prevalence of 
abdominal obesity was 52.6%, BMI≥25 kg/m2 -26.1%, hypertension-22.6%, high AIP-31.3% and FHS above 10% was 16.6%. The prevalence of 
low High Density Lipoprotein (HDL) was 37.5%, high Total cholesterol (Tc)-30.2%, high Low Density Lipoprotein (LDL) -23.6%, high Triglycerides 
(TG)-21.2%, low physical activity-46.4% and alcohol consumption-26.4%. In multivariate linear regression analyses, increasing age was associated 
with higher mean Tc, HDL, LDL, FHS (P<0.001) and hyperglycemia (p<0.005). In multivariate logistic regression analyses, Protease Inhibitor (PI) 
containing regimens were significantly associated with higher risks of abnormal: Tc, LDL, TG, AIP, abdominal obesity, hypertension, low HDL and 
lower risk of a FHS >10% compared to the non PI regimen. Conclusion: ART increases cardiometabolic risk. Integration of routine assessment 
for cardiometabolic risk factors and preventive interventions into HIV care programs in resource-limited settings is recommended. 
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Introduction 
 
Sub Saharan Africa (SSA) has the highest burden of HIV/AIDS, with 
an estimated 25.8 million people living with HIV and about 1.4 
million new infections in 2014 [1]. Antiretroviral therapy (ART) has 
improved the quality of life of people living with HIV (PLWH) and 
has improved life expectancy substantially [2, 3]. By June 2015, 5.8 
million PLWH were receiving ART globally, of which 10.7 million 
were in SSA [1]. As people on ART live longer, challenges of long-
term HIV infection, lifestyle changes, aging and the toxic effects of 
ART, are emerging. Risk factors for cardiovascular disease (CVD) 
among PLWH may be similar to the general population and include 
family history, age, male gender, hypertension, smoking, obesity, 
Diabetes mellitus and hyperlipidemia [4]. PLWH on ART have an 
estimated 10-year CVD risk greater than 20% [5]. The expected 
deaths attributable to CVD are projected to double to 2.4 million in 
2030 relative to reports from 2000 [6]. Mortality due to CVD in SSA 
including Uganda is estimated to be threefold higher than in 
Western Europe [7]. In industrialised countries where ART has been 
provided for longer periods, ART agents particularly Protease 
Inhibitors (PI), have been associated with cardiometabolic risk 
factors, including impaired glucose metabolism, dyslipidemia, 
obesity and hypertension [8] but this has not been demonstrated in 
African settings. There is evidence to suggest that baseline 
metabolic profiles and associations between HIV, ART and 
cardiometabolic risk factors may differ between populations [9]. In 
Uganda, about 31700 deaths in 2002 were due to CVD and there is 
evidence of increasing CVD-related mortality from verbal autopsy 
data from among HIV infected people [10]. Conversely, a home-
based cross-sectional study in eastern Uganda reported no effect of 
ART on CVD, but that study had few participants on ART, for a 
shorter duration and did not examine the specific effects of a PI 
regimen [11]. HIV prevalence in Uganda in 2014 was 7.4% and 
about 0.75 million (50%) of the 1.5 million PLWH were on ART of 
whom about 10% had HIV viral load above 1000 copies/ml [12]. 
The roll out of HIV viral load testing in Uganda and other African 
countries will increase detection of individuals with virological failure 
needing second line PI based ART [13]. In this study, we 
investigated the prevalence and predictors of, and the effect of ART 
on cardiometabolic risk among HIV-positive individuals who have 
been receiving ART for up to a decade. We specifically compared 
the adjusted mean differences and the risk of the various 
cardiometabolic risk factors between participants on a PI containing 
ART regimen and non PI ART regimen against the confounding 
effect of demographic, socio economic and behavioral factors. 
  
  
Methods 
 
Study design and setting: This was a cross-sectional study that 
utilised data collected at enrolment into a prospective clinical cohort 
established in 2013 to study the Complications of Long-Term 
Antiretroviral therapy among HIV-Positive Ugandan adults 
(CoLTART). The CoLTART study aims were to describe the 
metabolic and renal complications, clinical and virological outcomes 
among HIV-positive Ugandan adults on long-term ART. However, 
this analysis was a sub-study specifically aimed at evaluating the 
cardio-metabolic complications of long-term ART. The study setting 
was the (i) Former Development of ART in Africa (DART) study clinic 
that was established in 2003 in Entebbe, Central Uganda [14], and 
(ii) the former Rural Clinical Cohort (RCC) that was established 1990 
in south western Uganda where ART was introduced in 2004 [15]. 
  
Study population: The study sample selection was based on non-
probability sampling of all HIV-positive adults aged 18 years and 
above, from two former HIV cohorts; the DART trial and RCC, who 
were receiving ART and consenting to undergo all study procedures. 
Study information was given to potential participants by a study 
clerk. Individuals who were too sick to undergo study procedures or 
unable to give consent were excluded. Participants were either 
taking a PI containing ART regimen or Non PI containing regimen. 
Non PI regimen included a standard two Nucleoside Reverse 
Transcriptase inhibitor (NRTI) and one Non-NRTI. Some participants 
from the DART trial cohort were taking a triple nucleoside therapy 
consisting of 3 NRTI agents. The PI containing regimen consisted of 
a ritonavir boosted PI mainly Lopinavir in combination with one or 
two NRTI. 
  
Measurements: Socio-demographic, socio-economic status, 
medical history, behavioral and dietary exposures was obtained by 
self-report using a structured questionnaire. We used a modified 
WHO stepwise approach to surveillance questionnaire to collect 
cardiovascular risk data [16]. ART history data including initiation 
date and regimen substitutions and/or switches were obtained from 
the electronic databases of the two former ART cohorts. We 
measured the body weight using the Seca digital measuring scale 
and height using a portable Seca 213 Leicester stadiometer. Waist, 
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hip and mid-upper arm circumferences were measured using a non-
stretchable Seca 201 Ergonomic Circumference Measuring tape. 
Details of the methods for taking biophysical measurements and 
calibrating the equipment used have been described elsewhere [10]. 
Blood pressure and pulse rate were measured using the Omron M6 
comfort automatic blood pressure monitor. Fasting blood glucose 
(FBG), Low Density Lipoprotein (LDL), High Density Lipoprotein 
(HDL), Total Cholesterol (Tc) and Triglycerides (TG) were measured 
using the Cobas Integra 400 plus (Roche Diagnostics) as described 
elsewhere [17]. Viral loads were quantified using the Cobas 
Ampliprep/Taqman V2.0 HIV-1 viral load assay [Roche Molecular 
Diagnostic (RMD) ,NJ,USA] with a lower limit of detection of 20 
copies/ml. CD4+ cell counts were analysed using FACSCount or 
FACSCalibur machine [Becton Dickson, USA]. 
  
Variables and definitions: Cardiometabolic risk was defined as a 
high lifetime risk for CVD caused by specific factors including 
hypertension, dyslipidemia, hyperglycemia and obesity [18]. 
Hypertension was defined as systolic blood pressure (SBP)>140 
mmHg and/or diastolic blood (DBP) pressure>90 mmHg or being on 
anti-hypertensive medication [19, 20]. Dyslipidemia was defined as 
HDL<1 mmol/L, LDL>3.4 mmol/L, Tc>5.2 mmol/L, TG>1.69 
mmol/L or Tc-HDL ratio>5.1 or being on lipid lowering medicine 
[19, 20]. Hyperglycemia was defined as fasting blood glucose 
>7mmol/L or being on treatment for diabetes mellitus. Abdominal 
obesity was assessed using waist-hip ratio (WHR) cutoffs of 0.95 for 
men and 0.85 for women [21] or waist circumference (WC)>94 cm 
for men and>80cm for women. Abnormal BMI was defined as 
BMI>25 Kg/m2. Atherogenic index of plasma (AIP) was calculated 
as log10 (triglycerides/HDL). AIP of -0.3-0.1 was regarded as low 
risk, 0.1-0.24 medium risk and >0.24 high risk [22]. We calculated 
the 10 year Framingham risk score (FHS) using risk calculator 
graphs based on the Joint British Societies risk prediction charts 
[23]. We entered variables: age, gender, smoking status, diabetes 
status, HDL, Tc, SBP, and DBP in the online calculator tool. We 
chose a FHS of >10% to denote moderate to high risk of CVD. 
Socio demographic risk factors which included age, sex, marital 
status, level of formal education and occupation were assessed 
using subjective categories. Socioeconomic status (SES) was 
assessed using a household asset score (in tertiles). Behavioral and 
dietary risk factors including physical activity, alcohol intake, 
smoking, consumption of animal protein, fruit, vegetables, sugar 
and salt were categorised by frequency and intensity. ART regimen 
was categorized as PI containing or non PI containing. Baseline viral 
loads and CD4 counts were analyzed using subjective categories. 
Statistical methods 
  
Sample size considerations: We used results from a recent 
survey (round 22) on metabolic abnormalities in the background 
population (GPC) [10] as a basis for power calculations for different 
proportions of participants with a metabolic abnormality among 
those on a PI-containing ART regimen assuming that 10% of the 
participants in the non-PI containing ART regimen group have this 
abnormality. We also assumed a within group standard deviation of: 
(a) 1.0 mmol/L for Tc, (b) 0.8 mmol/L for LDL, (c). 0.5 mmol/L for 
HDL (d) 0.8 mmol/L for TG, (e) 1.6 mmol/L for FBG (f) 19 mm Hg 
for SBP and (g) 12 mm Hg for DBP. We assumed having at least 
200 participants on a PI-containing ART regimen and at least 800 
participants on a non PI ART regimen would provide sufficient 
power with which a given between group mean difference will be 
detected as statistically significant at the 5% level. 
  
Statistical analysis: Analyses were done in STATA 13 (Stata 
Corporation, College Station, USA). We summarized participants' 
characteristics at enrolment into the study and calculated the 
prevalence of the cardiometabolic risk factors. We compared the 
mean values of SBP, DBP, Tc, HDL, LDL, TG, HDL, AIP and FBG and 
FHS between PI-based and non-PI based ART regimens using 
general linear regression models, adjusted for duration on ART, age, 
sex, site, tobacco and alcohol consumption, physical activity, dietary 
variables, household asset score and CD4 cell count. Logistic 
regression was used to compare risks of hypertension, obesity and 
abnormal values for Tc, LDL, FBG, AIP, FHS, HDL and TG between 
the PI and non-PI based ART regimens adjusted for the same 
factors that were used in the linear models. 
  
Ethical considerations: The CoLTART study was approved by the 
Research and Ethics Committee of the Uganda Virus Research 
Institute and by the Uganda National Council for Science and 
Technology. All Participants gave signed or thumb-printed written 
informed consent. Participants were reimbursed their transport 
expenses and compensated for their time during the study 
procedures 
  
  
Results 
 
Baseline characteristics of study participants: Between July 
2013 and August 2014, 1024 participants were enrolled. Majority 
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were females (65%), most were aged 40 years and above (mean 
age 44.8, SD 8.0), 76% were on ART for 5 to 10 years (median 9.4 
years, IQR 6.1-9.8). Participants were mainly self-employed or small 
scale business owners (40%), 45% had incomplete primary or no 
education and 42% were of low SES. The prevalence of current 
tobacco consumption was (7.8%), current alcohol consumption 
(26.4%), consumption of animal protein>3 days a week (27.8%) 
and low intensity physical activity (46.4%). At enrollment 23% of 
the participants were on PI based ART regimen, 31.5% had CD4 
counts below 350 cells/ml and 17.9% had HIV viraemia above 1000 
copies/ml. More men than women reported: current smoking 
(15.6% vs 3.7%), current alcohol consumption (38.3% vs 20.1%), 
consuming animal protein on > 3 days per week (33.0% vs 25.1%) 
and moderate to high level physical activity (69.3% vs 45.3%) Table 
1. 
  
Prevalence of cardiometabolic risk factors: Overall, 52.6% had 
abdominal obesity (high WHR), 26.1% were obese or overweight 
(BMI ≥25 kg/m2), 30.2% had high Tc, 37.6% had low HDL, 23.6% 
had high LDL, 21.2% had high TG and 3.5% had hyperglycemia. 
The prevalence of hypertension was 22.6%, high AIP was 31.6% 
and 16.6% of the participants had FHS > 10%. There were gender 
differences in the prevalence of cardiometabolic risk factors; more 
women than men had; high Tc (33.3% vs 24.2%), low HDL (43.0% 
vs 27.4%), high LDL (27.8% vs 15.7%), high BMI (34.6% vs 
10.3%), abdominal obesity (68.5% vs 22.6%) and abnormal WC 
(58.1% vs 4.6%). More men than women had: high TG (26.0% vs 
18.7%), FHS >10% (30.5% vs 9.2%) and abnormal AIP (38.9% vs 
27.3%) Table 1. 
  
Factors affecting cardiometabolic risk factors among adults 
on long-term ART: The PI regimen was significantly associated 
with: higher mean Tc, HDL, LDL, TG and AIP (P< 0.001) Figure 
1 (A, B). Men had significantly lower mean HDL, higher mean TG, 
Tc:HDL ratios and AIP (P<0.005). Increasing age was significantly 
associated with higher mean Tc, HDL, LDL (P<0.001) and FBG 
(P=0.033). Participants who reported consuming animal proteins on 
at least 3 days in a week had a higher mean Tc (P=0.016), LDL 
(P<0.004), FBG (P=0.037), FHS (P=0.02), Tc:HDL ratio (P=0.029) 
and AIP (P=0.022). Duration on ART was associated with increase 
in mean HDL (P=0.01). Participants in the (P=0.014) and lower Tc: 
HDL ratio (P=0.005) Table 2. Participants on PI ART had lower SPB 
(P=0.060) and DBP (P<0.001). Urban site participants had 
significantly higher SBP (P=0.050) and WC (P<0.001). Men had had 
significantly higher mean SBP (P=0.004), higher mean WHR, lower 
mean WC and higher mean FHS (all P<0.001) and lower BMI 
(P=0.002). We found that increasing age was significantly 
associated with higher means of SBP, DBP, WHR, WC and FHS (all 
P<0.001). Increasing intensity of physical activity was significantly 
associated with lower; SBP, DBP, WC, and FHS (P<0.05). The FHS 
was significantly higher among current tobacco consumers 
(P<0.001) but lower among current alcohol consumers 
(P=0.018) Table 3. We observed lower HDL, higher AIP and FHS, 
with increasing SES (P<0.05). We observed lower mean HDL, higher 
mean Tc, LDL, Tc: HDL ratio and AIP with higher HIV viral loads 
(P<0.001). Increasing CD4 cell counts were associated with higher; 
HDL (P=0.009) and AIP (P<0.001) Table 2. 
  
Effect of PI-containing ART regimen on cardiometabolic risk 
adjusted for confounders: Compared to non PI regimens, PI 
regimen was independently associated with twofold risks of: high Tc 
(Adjusted risk ratio (aRR): 2.04, 95% CI: 1.67-2.50, P<0.001), high 
LDL (aRR: 1.70, 95% CI: 1.33-2.16, P<0.001), high TG (aRR: 2.47, 
95% CI: 1.90-3.21, P< 0.001) and high AIP (aRR: 1.57, 95% CI: 
1.27-1.93, P<0.001). PI regimen had; a 36% less risk of low HDL 
(aRR: 0.74, 95% CI: 0.59-0.93, P=0.007), a 49% lower risk of 
hypertension (aRR: 0.51, 95% CI 0.35-0.75, P<0.001), a 16% 
higher risk of abdominal obesity (aRR: 1.16, 95% CI: 1.02-1.33, 
P=0.034) and a 41% lower risk of having a FHS >10% (aRR: 0.59, 
95% CI: 0.41-0.84, P=0.002) Table 4, Figure 1 (C and D). 
  
  
Discussion 
 
In our Ugandan cohort of people on long-term ART, more than a 
half of participants had abdominal obesity, about one third had high 
BMI, high Tc, low HDL, high AIP, and almost a quarter had high TG, 
FHS > 10% and hypertension. Few participants had hyperglycemia. 
Age, gender, physical activity, high viral load and PI-based ART 
regimen significantly affected cardiometabolic risk factors. The 
prevalence of hypertension compares with that reported in a South 
African study with similar median age [21], but higher than that 
reported from an ART cohort of younger adults in Rakai-Uganda 
(8.0%), Mbarara-Uganda (5.2%) and Kenya (8.8%) albeit lower 
than what was reported from Urban Uganda (27%)(24-26). 
Although the differences might be attributed to variation in 
population characteristics and settings, the prevalence exceeded 
that from the background general population cohort (GPC)-13% 
[10]. The risk of hypertension was higher among individuals on non 
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PI-based ART. Other factors associated with elevated blood 
pressure included older age, low physical activity, urbanicity, male 
gender and lower viral loads. Consistent with other studies, we 
found a low prevalence of hyperglycemia (3.4%) [24-26], which 
was not affected by ART regimen [27] but significantly affected by 
increasing age [28]. The prevalence of abdominal obesity in our 
study is comparable to the 30% observed in a Southwestern 
Ugandan ART cohort [26] but was lower than that reported in the 
background GPC population-56% [10]. High prevalence of obesity 
among women than men has also been previously established by 
studies in SSA (24-26) and Europe [29]. The observed risk of 
obesity from PI-based ART corroborates results from a US based 
observational study [30] and is possibly attributed to ART associated 
metabolic aberrations and fat mal-distribution. Studies from 
developed countries attested to a high risk of abnormal non HDL 
cholesterol among individuals on PI ART [31]. We observed a higher 
prevalence of non HDL dyslipidemia but a lower prevalence of low 
HDL among patients on ART than that reported in the background 
population [10]. PI's might affect cholesterol metabolism in the liver 
and in adipocytes [32].The observed association between duration 
on ART and high mean HDL levels suggests a possible protective 
effect of long-term ART on aspects of cardiometabolic risk although 
no literature is available to support this. More men than women had 
a FHS >10%, which is comparable to findings from a study in 
central Uganda [33]. The male predominance could be driven by 
age since men tended to be older, and had higher SBP than women 
as observed in a US cohort [34]. 
  
The higher risk of a FHS >10% among participants on non PI 
compared to PI regimen could be driven by a high prevalence of 
hypertension among participants taking non PI ART. The observed 
non PI ART associated risk of hypertension compares with results 
from open label ART trials in 7 sub-Saharan African countries [35]. 
Unlike PI linked vascular complications [36], non PI ART has no 
known significant associated pathology other than fat 
misdistribution and dyslipidemia [37]. As ART improves survival, the 
observed effect of age on Tc:HDL ratio, Tc, LDL and hypertension 
highlights the potential risk of CVD in a population aging on ART. 
Age induced dyslipidemia is thought to be due to increased 
inflammation due to high levels of Tumor necrosis alpha (TNF- α) 
and interleukin-6 (IL-6) which interfere with lipid metabolism. Our 
men had higher mean TG consistent with studies in South Africa 
and the US [24, 38]. We chose AIP as cardiovascular risk 
stratification to assess the influence of atherogenic dyslipidemia (TG 
and LDL) in predicting coronary atherosclerosis and cardiovascular 
risk in both hypertensive and normotensive individuals [22]. Higher 
mean AIP in men has also been reported among HIV patients in 
Nigeria [39], probably due to the elevated TG among men. 
Consumption of animal protein was associated with elevation of 
both TG and AIP. The PI regimen was associated with higher risk of 
abnormal AIP probably due to PI associated dyslipidemia. 
Participants in the urban study site had significantly higher mean 
LDL and Tc: HDL SBP, DBP, WC and BMI than those from the rural 
study site. This is in line with findings in the general population 
linking increasing urbanicity to higher prevalence of CVD risk factors 
[40], underscoring the importance of the ongoing rural-urban 
transition [41]. The association between HIV viraemia and 
dyslipidemia had been demonstrated previously. Viraemia is thought 
to mediate dyslipidemia through promoting peroxidation which is 
responsible for alteration of cholesterol metabolism [42]. Our 
analysis was based on a relatively large cohort of participants who 
had been on ART for almost a decade which enabled assessment of 
long-term effects of ART on cardiometabolic risk. We measured 
fasting blood lipid and glucose levels which minimized 
misclassification. The wide age range and a relatively large number 
of individual level exposures minimized confounding. We used both 
AIP and FHS as a comprehensive way of stratifying cardiovascular 
risk prediction, although the value of these scales has not been 
assessed among HIV infected people in Africa. Prior screening for 
CVD and education against CVD risk factors may have influenced 
self-reported data such as physical activity alcohol, salt and tobacco 
consumption. We defined variables using Western reference cut 
offs, however our findings corroborate findings from other studies. 
In calculating the FHS, left ventricular hypertrophy was not 
radiologically assessed. 
  
  
Conclusion 
 
Cardiometabolic risk is an increasingly important co-morbidity 
among people on ART in SSA countries including Uganda. Both the 
PI and non PI ART are associated with increased cardiometabolic 
risk. The protective effect of PI on hypertension and HDL 
dyslipidemia deserves further investigation. Increased HIV viral load 
testing in SSA, will detect more PLWH on first line ART needing 
second line PI based ART. Integration of routine CVD risk 
assessment and preventive treatments into HIV care programs is 
recommended to prevent cardiovascular related mortality and 
morbidity. Emphasis on protective social-behavioral and dietary 
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modifications is also important especially in urban settings. The 
findings also underscore the need to investigate ART associated 
cardiovascular risk in children. Our findings will inform policy on 
target interventions in HIV care to reduce cardiovascular associated 
morbidity and mortality among HIV-positive people on ART in sub-
Saharan African settings 
 
What is known about this topic 
 HIV and ART increase cardiometabolic risk; 
 The PI regimen is known to increase cardiometabolic risk; 
 Duration on ART is associated with cardiometabolic risk. 
What this study adds 
 In SSA Antiretroviral Therapy irrespective of type of 
regimen is associated with cardiometabolic risk; 
 Duration on ART does not independently increase 
cardiometabolic risk in African settings; 
 With the advent of test and treat, routine cardiovascular 
risk assessment should be integrated into HIV care 
programs. 
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Table 1:  Characteristics of study participants at enrollment into the CoLTART study, by sex 
Characteristic All   [N=1024] Female [N=669] Males   [N=355] 
n     (%) n       (%) n    (%) 
  
Age in years 
18-34 111     (10.8) 86      (12.9) 25   (7.0) 
35-49 613     (59.9) 401    (59.9) 212   (59.7) 
50+ 300     (29.3) 182    (27.2) 118   (33.2) 
  
Level of education1 
  
Incomplete    primary/none 459     (45.0) 294    (44.0) 165   (46.7) 
Complete primary 156     (15.3) 104    (15.6) 51   (14.7) 
Secondary + 406     (39.8) 270    (40.4) 136   (38.5) 
  
  
Occupation1 
  
Peasant Farmer 322     (31.6) 205    (30.7) 117  (33.1) 
Gainful employment 210     (20.6) 132    (19.8) 78   (22.1) 
Self-employed / business 408     (40.0) 264    (39.6) 144  (40.4) 
Unemployed 80     ( 7.8) 66     ( 9.9 ) 14  ( 4.0 ) 
  
SES Score (tertiles)1 
  
Low 416     (42.1) 307    (47.8) 109   (31.6) 
Middle 378     (38.3) 240    (47.8) 138   (40.0) 
High 193     (19.6) 95    (14.8) 98   (28.4) 
  
Alcohol consumption1 
Never 379     (37.5) 277    (41.8) 102   (29.1) 
Ever >1 month ago 366     (36.2) 252    (38.1) 114   (32.6) 
Within < 1 month 267     (26.4) 133    (20.1) 134   (38.3) 
Animal proteins consumption 
 (days/week) 
0 269     (26.6) 204    (30.8) 65   (18.5) 
1- 2 462     (45.6) 292    (44.1) 170   (48.4) 
3+ 282     (27.8) 166    (25.1) 116   (33.0) 
Tobacco consumption2 Never 843     (82.6) 625    (93.7) 218   (61.8) 
Ex-smoker 97     ( 9.5) 17    ( 2.5 ) 80   (22.7) 
Current 80      ( 7.8) 25    ( 3.7 ) 55   (15.6) 
Physical activity level2 Low 473     (46.4) 365    (54.7) 108   (30.7) 
Moderate - high 546     (53.6) 302    (45.3) 244   (69.3) 
Total duration on ART (Years) 0-<5 243     (23.7) 150    (22.4) 93  (26.2) 
5-<9 124     (12.1) 74    (11.1) 50   (14.1) 
9+ 657     (64.2) 445    (66.5) 212   (59.7) 
ART regimen Non PI based ART 788     (77.0) 519    (77.6) 269   (75.8) 
PI based ART 236     (23.0) 150    (22.4) 86   (24.2) 
Cholesterol  
(>5.2 mol/L) 
No 708     (69.8) 442    (66.1) 266   (75.8) 
Yes 306     (30.2) 221    (33.3) 85   (24.2) 
HDL (<1 mmol/L)3 No 633     (62.4) 378    (57.0) 255   (72.6) 
Yes 381     (37.6) 285    (43.0) 96   (27.4) 
LDL (>3.4 mmol/L)3 
  
No 775     (76.4) 479    (72.2) 296   (84.3) 
Yes 239     (23.6) 184    (27.8) 55   (15.7) 
Triglycerides 
 (>1.69 mmol/L)3        
No 798     (78.8) 539    (81.3) 259   (74.0) 
Yes 215     (21.2) 124    (18.7) 91  (26.0) 
Glucose (>6.0 mmol/L) No 979     (96.5) 640    (96.5) 339   (96.3) 
Yes 36     ( 3.5) 23    (3.5  ) 13  ( 3.7 ) 
Atherogenic risk (AIP) 4 
(log10(triglycerides/HDL) 
No 696     (68.7) 482    (72.7) 214   (61.1) 
Yes 317     (31.3) 181    (27.3) 136   (38.9) 
Body Mass Index  (kg/m2)5 <18.5 103     (10.3) 54     ( 8.3 ) 49   (14.1) 
18.5–24.9 637     (63.6) 374    (57.2) 263   (75.6) 
>25 282     (26.1) 226    (34.6) 36   (10.3) 
Waist/hip ratio (WHR) 5 
>0.95(men)/>85(women) 
Normal 478     (47.4) 207    (31.5) 271   (77.4) 
Abnormal 530     (52.6) 451    (68.5) 79   ( 2.6 ) 
Hypertension5 
  
No 782     (77.4) 505    (76.6) 277   (78.9) 
Yes 228     (22.6) 154     (23.4) 74  (21.1) 
Baseline Viral loads6 
 (copies/ml) 
  
< 1000 813     (82.1) 535    (82.8) 278   (80.8) 
1000 – 10,000 53     (5.35) 39     ( 6.0 ) 14   ( 4.1 ) 
>10,000 124     (12.5) 72    (11.2) 52   (15.1) 
Baseline CD4 cell counts6 
 (cells/ml) 
  
< 350 300    (31.5) 163    (24.5) 137   (40.5) 
351 – 500 294    (30.8) 191    (31.0) 103   (30.5) 
> 500 360    (37.7) 262    (42.5) 98   (29.0) 
Data was missing on; SES1-(27 women and 10 men), occupation1 (2 women and 1 man), Level of education1(1 woman and 3 men), consumption of Alcohol1 and animal protein1 (7 women and 5 men). Data was missing 
for; Tobacco consumption2 (2 women and 2 men) and Physical activity2 (2 women and 3 men). Data was Missing on; Serum Tc3, HDL3 LDL3, TG3 Glucose (6 women and 4 men). Calculation of AIP4 excluded 6 women and 3 
men with missing data. There was missing data on; HT5 (10 Women and 4 men) BMI5 (15 women and 7 men), WHR5 and WC (11 women and 5 men),  Baseline VL6 (23 women and 11 men) and Baseline CD4 cell count6 ( 
53 women, 7 men)  
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Table 2:  adjusted mean differences in bio-chemical risk factors for cardiovascular disease among adults on long-term ART 
Risk Factor Tc (mmol/L) HDL (mmol/L) LDL (mmol/L) Triglycerides(mmol/L) Glucose(mmol/L) Tc: HDL ratio AIP 
aMD (95% CI) aMD (95% CI) aMD (95% CI) aMD (95% CI) aMD (95% CI) aMD (95% CI) aMD (95% CI) 
ART type P-value <0.001 <0.001 <0.001 <0.001 0.902 0.731 <0.001 
non-PI   --- --- --- --- --- --- --- 
PI   0.75 (0.54-0.96) 0.15 (0.07-0.23) 0.40 (0.24-0.57) 0.51 (0.24-0.77) -0.01 (-0.18-0.16) 0.05 (-0.22-0.32) 0.11 (0.06-0.16) 
         
Duration on ART P-value 0.550 0.01 0.935 0.909 0.078 0.261 0.423 
0-<5 Years   --- --- --- --- --- --- --- 
5-<9 Years   0.05 (-0.24-0.33) 0.07 (-0.04-0.18) -0.03 (-0.26-0.20) 0.05 (-0.31-0.42) -0.00 (-0.23-0.22) -0.17 (-0.54-0.20) -0.04 (-0.11-0.03) 
9+    Years   0.19 (-0.160.54) 0.20 (0.07-0.33) 0.01 (-0.26-0.29) 0.09 (-0.35-0.54) 0.28 (0.01-0.56) -0.37 (-0.82-0.08) -0.05 (-0.14-0.04) 
Study site P-value 0.301 <0.001 0.014 0.576 0.671 0.005 0.306 
Entebbe (peri-rban)   --- --- --- --- --- --- --- 
Kyamulibwa (Rural)   -0.17 (-0.50-0.16) 0.20 (0.07-0.32) -0.33 (-0.59-0.06) -0.12 (-0.54-0.30) -0.06 (-0.32-0.21) -0.61 (-1.04--0.18) -0.04 (-0.13-0.04) 
Sex P-value 0.165 <0.001 0.147 0.005 0,406 <0.001 <0.001 
 Female   -- -- - - -- -- -- 
Males   -0.14 (-0.34-0.06) -0.18 (-0.26--0.11) -0.12 (-0.27-0.04) 0.36 (0.11-0.61) 0.07 (-0.09-0.22) 0.47 (0.22-0.73 0.12 (0.07-0.17) 
Age (years) P-value <0.001 <0.001 <0.001 0.691 0.033 0.149 0.456 
18-34   --- --- --- --- --- --- --- 
35-49   0.60 (0.32-0.87) 0.09 (-0.02-0.20) 0.47 (0.25-0.69) 0.15 (-0.20-0.50) 0.21 (-0.01-0.43) 0.33 (-0.03-0.69) 0.04 (-0.03-0.11) 
50+   0.96 (0.66-1.26) 0.20 (0.09-0.32) 0.68 (0.44-0.92) 0.15 (-0.23-0.53) 0.31 (0.08-0.55) 0.37 (-0.02-0.75) 0.03 (-0.05-0.10) 
Consumes tobacco P-value 0.075 0.045 <0.001 0.156 0.128 0.039 0.121 
Never   --- --- --- --- --- --- --- 
Ex-smoker   -0.25 (-0.54-0.05) 0.03 (-0.08-0.15) -0.38 (-0.62--0.15) 0.32 (-0.06-0.69) 0.01 (-0.22-0.25) -0.32 (-0.70-0.07) 0.01 (-0.07-0.08) 
Current smoker   -0.30 (-0.63-0.02) 0.16 (0.03-0.28) -0.43 (-0.69--0.17) -0.14 (-0.56-0.28) -0.26 (-0.52-0.00) -0.48 (-0.90--0.05) -0.08 (-0.17--0.00) 
Consumes alcohol P-value 0.002 0.002 <0.001 0.202 0.769 0.003 0.155 
Never   --- --- --- --- --- --- --- 
Ever>1month ago   0.30 (0.11-0.49) 0.04 (-0.03-0.11) 0.20 (0.04-0.35) 0.12 (-0.13-0.37) -0.01 (-0.17-0.14) 0.13 (-0.12-0.38) -0.00 (-0.05-0.05) 
within<1month   -0.01 (-0.23-0.20) 0.11 (0.03-0.20) -0.10 (-0.27-0.07) -0.12 (-0.39-0.15) 0.05 (-0.13-0.22) -0.34 (-0.62--0.06) -0.05 (-0.10-0.01) 
Animal proteins 
consumption 
(days/week) 
P-value 0.016 0.341 0.004 0.844 0.037 0.029 0.022 
0 --- --- --- --- --- --- --- 
1 or   2 0.02 (-0.18-0.23) 0.06 (-0.02-0.13) 0.00 (-0.16-0.16) -0.02 (-0.28-0.24) -0.10 (-0.26-0.06) -0.08 (-0.35-0.18) -0.04 (-0.09-0.01) 
3+ 0.29 (0.05-0.53) 0.03 (-0.06-0.12) 0.26 (0.07-0.45) 0.05 (-0.25-0.36) 0.10 (-0.09-0.30) 0.27 (-0.05-0.58) 0.02 (-0.04-0.08) 
SES Score (tertiles) P-value 0.552 0.005 0.415 0.412 0.511 0.111 0.032 
Low   --- --- --- --- --- --- --- 
Medium   0.09 (-0.28-0.09) -0.10 (-0.17—0.03) 0.04 (-0.19-0.11) 0.17 (-0.08-0.42) 0.08 (-0.08-0.23) 0.20 (-0.04-0.45) 0.05 (0.01-0.10) 
High   -0.01 (-0.24-0.22) -0.11 (-0.20--0.03) 0.08 (-0.10-0.27) 0.06 (-0.25-0.37 0.10 (-0.10-0.29) 0.29 (-0.02-0.59) 0.06 (0.01-0.12) 
CD4counts(cells/ml P-value 0.782 0.009 0.697 0.055 0.389 0.077 0.001 
<350   ---- --- ---- --- ---- ---- --- 
350 – 500   0.05 (-0.16-0.26) 0.02 (-0.06-0.10) 0.06 (-0.11-0.23) -0.02 (-0.31-0.27) 0.03 (-0.15-0.21) -0.10 (-0.38-0.18) 0.01 (-0.07-0.04) 
>500   0.07 (-0.14-0.29) 0.09 (0.17--0.01 0.07 (-0.10-0.24) 0.28 (-0.01-0.57) 0.12 (-0.06-0.30) 0.20 (-0.08-0.48) 0.07 (0.02-0.13) 
VL (copies ml) P-value <0.001 <0.001 <0.001 0.584 0.435 0.001 <0.001 
<1000   --- --- --- ---- ---- --- ---- 
1000 – 9999   0.14 (-0.50-0.23) -0.22 (-0.36--0.08) 0.03 (-0.26-0.32) 0.01 (-0.48-0.51) -0.08 (-0.39-0.22 0.46 (-0.03-0.94) 0.09 (0.00-0.18) 
10,000+   0.81 (-1.09-0.54) -0.45 (-0.56--0.35) 0.45 (0.67--0.23) 0.20 (-0.18-0.57) -0.14 (-0.38-0.09) 0.93 (0.56-1.30) 0.26 (0.19-0.33) 
P-value from the likelihood ratio test, aMD - Adjusted mean differences from the reference values (---) , VL – Viral loads,  PI-protease inhibitor, SES score-social economic status score, HDL-high density lipoprotein, LDL-low density 
lipoprotein, Tc-total cholesterol, AIP –Mean Atherogenic Index for Plasma  (log10(Triglycerides/HDL). 
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Table 3:  Adjusted mean differences (aMD) in bio-physical risk factors for cardiovascular disease among adults on long-term ART 
Risk Factor Systolic  BP (mmHg) Diastolic BP (mmHg) Waist/hips ratio WC (cm) BMI (kg/m2)             FHS 
   aMD (95% CI)       aMD (95% CI)     aMD (95% CI) aMD (95% CI) aMD (95% CI)    aMD (95% CI) 
ART regimen at 
enrolment 
p-value 
  
0.062 <0.001 0.067 0.267 0.084 0.463 
Non- PI   --- --- --- --- --- --- 
PI   -3.031 (-6.30-0.2) -3.771 (-6.3--2.3) 0.010 (-0.001-0.02) -0.9 (-2.5-0.7) -1.9 (-4.1-0.3) -0.3 (-1.2-0.5) 
Study site P-value 0.050 0.092 0.239 <0.001 0.066 0.125 
Entebbe(peri-urban)   --- --- --- --- --- --- 
Kyamulibwa (rural)   -4.77 (-9.6--0.07) -2.54 (-5.5--0.45) -0.010 (-0.027-0.007) -5.7 (-8.2--3.1) -3.2 (-6.7-0.2) -1.0 (-2.3-0.3) 
Sex P-value 0.004 0.849 <0.001 <0.001 0.002 <0.001 
Females ---- --- --- --- --- --- --- 
Males ---- 4.4 (1.4-7.4) 0.2 (-1.7-2.1) 0.034 (0.024-0.044) -3.4 (-4.9--1.9) -3.3 (-5.4--1.2) 3.2 (2.3-4.0) 
Age (years) P-value <0.001 <0.001 <0.001 <0.001 0.377 <0.001 
18-34 ---- --- --- --- --- --- --- 
35-49 ---- 5.9 (1.7-10.1) 4.3 (1.6-6.9) 0.011 (-0.003-0.025) 3.0 (0.8-5.1) 1.7 (-1.2-4.6) 1.7 (0.5-2.8) 
50+ ---- 15.4 (10.8-20.0) 7.3 (4.5-10.1) 0.028 (0.012-0.043) 4.7 (2.4-7.0) 0.8 (-2.4-3.9) 8.1 (6.9-9.4) 
Animal proteins 
consumption 
(days/week) 
P-value 0.468 0.336 0.158 0.045 0.161 0.019 
0 --- --- --- --- --- --- 
1 or 2 -0.2 (-3.4-2.9) -1.1(-3.0-0.8) -0.009 (-0.019-0.001) 0.7 (-0.9-2.3) 0.7 (-1.4-2.8) -0.4 (-1.2-0.5) 
3+ 1.6 (-2.0-5.3) 0.1 (-2.2-2.4) -0.002 (-0.014-0.010) 2.2 (0.4-4.1) 2.3 (-0.2-4.9) 0.8 (-0.2-1.8) 
Physical activity 
 intensity 
p-value 
  
0.014 <0.001 0.859 0.018 0.073 0.010 
Low ---- --- --- --- --- --- --- 
Moderate-High   -3.7 (-6.6--0.7) -3.9 (-5.7--2.1) -0.001 (-0.011-0.009) -1.8 (-3.3--0.3) -1.8 (-3.9-0.2) -1.0 (-1.8 - -0.2) 
SES score (tertiles) P-value 0.483 0.444 0.553 0.134 0.902 0.011 
Low ---- --- --- --- --- --- --- 
Medium ---- -1.25 (-4.20-1.69) -0.95 (-2.76-0.88) -0.01(-0.02-0.01) 1.12 (-0.34-2.59) -0.01 (-0.18-0.16) 0.3 (-0.5 – 1.0) 
High   0.80 (-2.85-4.44) 0.29 (-1.96-2.54) -0.01 (-0.02-0.01) 1.66 (-0.15-3.46) 0.29 (-1.96-2.54) 1.4 (0.5 – 2.3) 
Tobacco consumption P-value 0.31 0.16 0.85 0.31 0.23 <0.001 
Never ---- --- --- --- --- --- --- 
Ex-smoker ---- 0.2 (-4.4-4.7) 0.4 (-2.4-3.2) 0.002 (-0.01-0.02) -0.6 (-2.9-1.6) 2.6 (-0.5-5.7) 4.3 (3.1-5.5) 
Current smoker ---- -3.8 (-8.8-1.2) -2.8 (-5.9-0.3) -0.004 (-0.02-0.01) -1.9 (-4.4-0.6) 1.2 (-2.3-4.6) 3.1 (1.7-4.4) 
Alcohol consumption P-value+ 0.56 0.31 0.35 0.20 0.72 0.018 
Never ---- --- --- --- --- --- --- 
Ever>1month ago ---- 0.7 (-2.3-3.6) 0.4 (-1.4-2.3) -0.01 (-0.020-0.003) -1.1 (-2.5-0.4) -0.0 (-2.1-2.0) 0.5 (-0.3-1.3) 
within<1month   1.8 (-1.5-5.1) 1.5 (-0.5-3.6) -0.01 (-0.020-0.005) 0.3 (-1.4-1.9) 0.8 (-1.4-3.1) -0.7 (-1.6-0.2) 
CD4 counts (cells/ml) P-value 0.18 0.04 0.23 0.02 0.74 0.31 
<350 ---- ---- --- ---- ---- --- --- 
350 – 500 ---- 2.29 (-1.08-5.66) 1.29 (-0.78-3.37) 0.005 (-0.006-0.016) 0.56 (-1.117-2.230) 0.194 (-2.20-2.59) 0.3 (-0.6 – 1.2) 
>500   3.09 (-0.28-6.46) 2.68 (0.60-4.76) 0.010 (-0.001-0.021) 2.22 (0.544-3.891 0.88 (-1.52-3.27) 0.7 (-0.2 – 1.5) 
VL (copies /ml) P-value 0.011 0.073 0.187 0.15 0.81 0.728 
<1000 ---- ----- ---- -- -- -- --- 
000 – 9999 ---- -5.50 (-11.34-0.34) -1.70 (-5.32-1.92) 0.01 (-0.01-0.03) 2.576 (-0.30-5.45) -0.39 (-4.92-4.15) 0.6 (-0.9 – 2.1) 
10,000+ ---- -5.37 (-9.57--1.18) -2.90 (-5.45--0.26) 0.01 (-0.003-0.02) 1.015 (-1.05 -3.08) -1.058 (-4.32-2.20) 0.2 (-0.9 – 1.3) 
P-value from the likelihood ratio test, aMD -Average mean differences from the reference values ( --- ), PI-protease inhibitor, SES score-social economic status score, HDL-high density lipoprotein, LDL-low density lipoprotein, Tc-total cholesterol,  VL-Viral loads, 
BMI-Body mass index, BP –Blood pressure, WC – Waist circumference and  FHS- 10 year Framingham’s risk score 
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Table 4: risk of abnormal values of blood pressure and other CVD risk factors 
CVD Risk factor 
1No. abnormal/Total   (%) Risk of abnormal values 
of cardio metabolic risk 
factors 
Adjusted risk ratio 
Non-PI, n=788 and PI, n=236 
P-Value+ 
(95% CI) 
Total cholesterol ≥5.2 umol/L 
  
P<0.001 
Non-PI regimen 185/783 (23.6%) 0.25 1 
PI regimen 121/231 (52.4%) 0.50 2.04 (1.67-2.5) 
Abnormal HDL 
  
P=0.007 
Non-PI regimen 313/783 (40.0%) 0.39 1 
PI regimen 68/231 (29.4%) 0.29 0.74  (0.59 -0.93 ) 
LDL  ≥3.4 mmol/L 
  
P<0.001 
Non-PI regimen 146/783 (18.6%) 0.20 1 
PI regimen 93/231(40.3%) 0.34 1.70  (1.33 -2.16 ) 
Total cholesterol/ HDL ratio ( >5.1) 
  
P=0.938 
Non-PI regimen 103/783 (13.1 %) 0.14 1 
PI regimen 42/231 (18.2%) 0.14 0.99  (0.68 -1.43 ) 
Triglycerides ≥ 1.69 mmol/L 
  
P<0.001 
Non-PI regimen 116/782 (14.8%) 0.15 1 
PI regimen 999/231 (42.9%) 0.38 2.47  (1.90 -3.21 ) 
Glucose (>6 mmol/L) 
  
P=0.394 
Non-PI regimen 20/783 (2.5 %) 0.03 1 
PI regimen 5/232 (2.2 %) 0.02 0.63  (0.21 -1.92 ) 
Hypertension (SBP ≥140/DBP ≥90) mmHg 
  
P<0.001 
Non-PI regimen 195/775 (25.2%) 0.25 1 
PI regimen 33/235 (14.0%) 0.13 0.51  (0.35 -0.75) 
AIP (log10(Triglycerides/HDL) ≥0.1 
  
P<0.001 
Non-PI regimen 214/782 (27.4%) 0.27 1 
PI regimen 103/231 (44.6%) 0.42 1.57 (1.27-1.93 
Abnormal BMI (>25Kg/m2) 
  
P=0.970 
Non-PI regimen 193/770  (25.1% 0.25 1 
PI regimen 69/232 (29.7%) 0.25 1.00 (0.78-1.30) 
Abnormal waist circumference 
[>=94cm(men)/>=80cm(women)] 
  
 
  
 
P=0.831 
Non-PI regimen 303/773  (39.2%) 0.39 1 
PI regimen 95/235 (40.4%) 0.38 0.98 (0.82-1.17) 
Abnormal Waist/hips ratio     
[>0.95(men)/>85(women)]  
  
 
P=0.034 
Non-PI regimen 396/773 (51.2%) 0.49 1 
PI regimen 134/235(57.0%) 0.57 1.16 (1.02-1.33) 
Framingham score (>10%) 
  
P=0.002 
Non-PI regimen 138/770 (17.9%) 0.20 1 
PI regimen 28/230 (12.2%) 0.12 0.59 (0.41-0.84) 
1A few participants with missing outcome variables. CVD-cardiovascular Disease, PI-protease inhibitor, HDL-high density lipoprotein, LDL-low density lipoprotein, 
AIP-Atherogenic index for plasma, BMI-Body mass index, P-Value+ from the likelihood ratio test 
Abnormal HDL - HDL<1 mmol/L (Men),<1.3 mmol/L (Females) 
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Figure 1: Effect of ART on Cardiometabolic risk factors 
 
